Fundz Deep Dive
Everything you need to win Clearside Biomedical, Inc. — in one platform.
Who to reach, what to say, and why now on Clearside Biomedical, Inc. — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Clearside Biomedical, Inc. — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Clearside Biomedical's Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy
Nov 07, 2024•over 1 year ago
Contract Type
partnership
AlpharettaInformation TechnologyBiotechnologyHealthcarePharmaceuticalBiopharmaDescription
Clearside Biomedical, Inc. (Nasdaq: CLSD)'s Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. for ARVN001, branded in the U.S. as XIPERE®, for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months